Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Diagnostics Preliminary Q4 Revenues Rise 94 Percent

NEW YORK – Accelerate Diagnostics reported on Monday that its preliminary fourth quarter revenues rose 94 percent but still fell short of the company's expectations.

For the quarter ended December 30, 2019 Accelerate Diagnostics expects total revenues of $3.5 million, up from $1.8 million in the year-ago quarter. For the full year, total revenue is expected to be $9.3 million, up 63 percent compared to its full-year 2018 revenues of $5.7 million.

The analysts' average estimates were for Q4 revenues of $4.8 million and for full-year revenues of $10.7 million.

The Tucson, Arizona-based company said that it had 137 commercially contracted Pheno instruments in the fourth quarter, and 304 for full-year 2019, within range of the lower end — or 300 to 400 placements — of the firm's targeted placements in 2019 that it guided to earlier.

Despite the sharp year-over-year uptick in Q4 revenues, incoming CEO Jack Phillips said that its still failed to meet expectations. He attributed the shortfall to continued delays of multisite contracted customers going clinically live, delaying their generating consumables revenue. The firm has previously cited delays in getting its instruments up and running in labs as the reason for slower than expected revenue growth.

Nonetheless, Phillips said in a statement that Accelerate is "pleased with our overall placement trajectory after doubling our contracted Phenos in 2019 and we remain confident in our outlook for continued strong adoption in 2020."

The firm's CEO transition was announced last month. Phillips will be replacing current CEO Larry Mehren on February 1, 2020. 

Net cash used is expected to be approximately $58 million for full-year 2019, the firm said, resulting in cash on hand of $109 million.

Accelerate Diagnostics' shares fell more than 2 percent to $17.94 in morning trading on the Nasdaq.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.